- ￥700 - 1900
- 齐源
- 100307
- 国产/进口
- 2025年07月15日
- FC
- 仓鼠
- 小鼠
7 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
CD3ε
- 级别：
CD3ε Antibody
- 目录编号：
CD3ε Antibody
- 克隆性：
单克隆
- 抗原来源：
仓鼠
- 保质期：
CD3ε Antibody
- 抗体英文名：
anti-mouse CD3ε Antibody-PE
- 抗体名：
CD3ε Antibody
- 标记物：
PE
- 宿主：
仓鼠
- 适应物种：
小鼠
- 免疫原：
CD3ε Antibody
- 亚型：
CD3ε Antibody
- 形态：
CD3ε Antibody
- 应用范围：
FC
- 保存条件：
2-8℃
- 浓度：
0.2 mg/ml
- 规格：
50 µg/200 µg
| 规格： | 50 µg | 产品价格： | ￥700.0 |
|---|---|---|---|
| 规格： | 200 µg | 产品价格： | ￥1900.0 |
anti-mouse CD3ε Antibody-PE详细如下：
Description ：CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Igsuperfamily and primarily expressed on T cells, NK-T cells, and at different levels onthymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with theCD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCRsignal transduction, T cell activation, and antigen recognition by binding the peptide/MHCantigen complex.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Armenian Hamster
Immunogen ：H-2K -specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography, and conjugated with PE under optimalconditions.
Concentration ：0.2 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 cellsin 100 µl. It is recommended that the reagent be titrated for optimal performance for eachapplication.
Excitation Laser ：Blue Laser (488 nm)、Green Laser (532 nm)、Yellow-Green Laser (561 nm)
Description ：CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Igsuperfamily and primarily expressed on T cells, NK-T cells, and at different levels onthymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with theCD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCRsignal transduction, T cell activation, and antigen recognition by binding the peptide/MHCantigen complex.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Armenian Hamster
Immunogen ：H-2K -specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography, and conjugated with PE under optimalconditions.
Concentration ：0.2 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 cellsin 100 µl. It is recommended that the reagent be titrated for optimal performance for eachapplication.
Excitation Laser ：Blue Laser (488 nm)、Green Laser (532 nm)、Yellow-Green Laser (561 nm)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
13. Ko SY, et al. 2005. J. Immunol. 175:3309.
14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
20. Guo Y, et al. 2008. Blood 112:480. PubMed
21. Kenna TJ, et al. 2008. Blood 111:2091.
22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
27. Qi Q, et al. 2009. Blood 114:564. PubMed
28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations：
1. Guo H, Cooper S, Fried-man A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
3. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
4. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
5. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
6. Sierro F, et al. 2017. Immunity. 47:374. PubMed
7. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
8. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
9. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
10. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
11. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
12. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
13. Ko SY, et al. 2005. J. Immunol. 175:3309.
14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
20. Guo Y, et al. 2008. Blood 112:480. PubMed
21. Kenna TJ, et al. 2008. Blood 111:2091.
22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
27. Qi Q, et al. 2009. Blood 114:564. PubMed
28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations：
1. Guo H, Cooper S, Fried-man A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
3. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
4. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
5. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
6. Sierro F, et al. 2017. Immunity. 47:374. PubMed
7. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
8. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
9. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
10. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
11. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
12. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
相关实验
抗体二抗上连接有荧光染料。直接标记染色背景低，实验程序少尽量减少实验工序和过程，以保证实验的真实和准确性。因此在条件允许的范围内，建议尽量用直接标记的抗体进行实验。 3、流式抗体荧光标记的选择： 如果实验中检测单一指标：不同荧光标记在不同的仪器上强度不同。以某仪器为例：PE ＞APC ＞PE-Cy5 ＞PerCP ＞FITC ＞PerCP-Cy5.5，通常来说，PE最强，适用于弱表达抗原。FITC强度较弱，适用于强表达抗原，使用范围比较广。用户需根据检测的目标蛋白进行具体选择。 如果同时检测多个
- 3) 及 CD45 -PE (HI30，白细胞标志) 抗体染色后，进行流式分析，死细胞以 DAPI 染色先行排除，左右分别为分选前后的细胞群分布。 总结： 几次实验的结果，使用 Fab-TACS® Gravity column 来从全血直接进行 CD3+ T 细胞分选，平均得率为 84.5%，纯度大于 90%，细胞存活率高于 95%，且目标细胞不含标记，贴近天然，使下游实验更精确。
: 由此步骤开始，流出的溶液包含目标细胞，请使用新的试剂管收集！首先，加入 1 ml 的 biotin 洗脱液，孵育 2 min。其次，加入 10 ml biotin 洗脱液，洗脱目标细胞。d) 再加入 10 ml biotin 洗脱液，洗下剩余的目标细胞。最后两步骤所收集的液体含分选出的目标细胞。(4) 结果分析以下流式图为从 7.5 ml 全血中，选出 CD3+ T 细胞的数据。选后细胞以 CD3-APC（OKT-3） 及 CD45-PE（HI30，白细胞标志） 抗体染色后，进行流式分析，死细胞
文献支持
抗小鼠 CD3ε 荧光标记PE 抗体
￥700 - 1900
